Cadi Irvine1, Kieren J Egan2, Zara Shubber3, Koen K A Van Rompay4, Rachel L Beanland1, Nathan Ford1. 1. Department of HIV/AIDS, World Health Organization. 2. Department of Mental Health and Psychiatry, University Hospitals of Geneva, Switzerland. 3. Department of Infectious Disease Epidemiology, Imperial College London, United Kingdom. 4. California National Primate Research Center, University of California, Davis.
Abstract
BACKGROUND: The efficacy of antiretrovirals as postexposure prophylaxis (PEP) to prevent viral acquisition was demonstrated in nonhuman primate models of human immunodeficiency virus (HIV) in the early 1990s. To complement the evidence base for efficacy of HIV PEP in humans, we systematically reviewed the published data on PEP efficacy across animal studies. METHODS: PubMed, Web of Science, and Embase were searched from inception to 31 May 2014 for randomized and nonrandomized studies reporting seroconversions among uninfected animals exposed to HIV or simian immunodeficiency virus, irrespective of route of exposure. Seroconversion risk data were pooled using random-effects models, and associations explored through meta-regression. RESULTS: Twenty-five studies (408 primates) were included for review. The risk of serconversion was 89% lower among animals exposed to PEP compared with those that did not receive PEP (odds ratio, 0.11 [95% confidence interval, .05-.23]). Heterogeneity was low (I(2) = 0.0%). In meta-regression, a significant association was found between timing of PEP and seroconversion and the use of tenofovir compared with other drugs. CONCLUSIONS: This review provides further evidence of the protective benefit of PEP in preventing HIV acquisition, and the importance of initiating PEP as early as possible following virus exposure.
BACKGROUND: The efficacy of antiretrovirals as postexposure prophylaxis (PEP) to prevent viral acquisition was demonstrated in nonhuman primate models of human immunodeficiency virus (HIV) in the early 1990s. To complement the evidence base for efficacy of HIV PEP in humans, we systematically reviewed the published data on PEP efficacy across animal studies. METHODS: PubMed, Web of Science, and Embase were searched from inception to 31 May 2014 for randomized and nonrandomized studies reporting seroconversions among uninfected animals exposed to HIV or simian immunodeficiency virus, irrespective of route of exposure. Seroconversion risk data were pooled using random-effects models, and associations explored through meta-regression. RESULTS: Twenty-five studies (408 primates) were included for review. The risk of serconversion was 89% lower among animals exposed to PEP compared with those that did not receive PEP (odds ratio, 0.11 [95% confidence interval, .05-.23]). Heterogeneity was low (I(2) = 0.0%). In meta-regression, a significant association was found between timing of PEP and seroconversion and the use of tenofovir compared with other drugs. CONCLUSIONS: This review provides further evidence of the protective benefit of PEP in preventing HIV acquisition, and the importance of initiating PEP as early as possible following virus exposure.
Authors: Matthew R Beymer; Ryan M Kofron; Chi-Hong Tseng; Robert K Bolan; Risa P Flynn; Jennifer M Sayles; Mario J Perez; Wilbert C Jordan; Raphael J Landovitz Journal: Int J STD AIDS Date: 2017-11-29 Impact factor: 1.359
Authors: Egidio Brocca-Cofano; Cuiling Xu; Katherine S Wetzel; Mackenzie L Cottrell; Benjamin B Policicchio; Kevin D Raehtz; Dongzhu Ma; Tammy Dunsmore; George S Haret-Richter; Karam Musaitif; Brandon F Keele; Angela D Kashuba; Ronald G Collman; Ivona Pandrea; Cristian Apetrei Journal: J Virol Date: 2018-08-16 Impact factor: 5.103
Authors: Matthew R Beymer; Robert E Weiss; Robert K Bolan; Ryan M Kofron; Risa P Flynn; David L Pieribone; Sonali P Kulkarni; Raphael J Landovitz Journal: Open Forum Infect Dis Date: 2017-04-04 Impact factor: 3.835
Authors: William C Goedel; Daniel Hagen; Perry N Halkitis; Richard E Greene; Marybec Griffin-Tomas; Forrest A Brooks; DeMarc Hickson; Dustin T Duncan Journal: AIDS Care Date: 2016-12-02
Authors: Leopold Ndemnge Aminde; Noah F Takah; Jean Jacques N Noubiap; Maxime Tindong; Calypse Ngwasiri; Ahmadou M Jingi; Andre Pascal Kengne; Anastase Dzudie Journal: BMC Public Health Date: 2015-11-06 Impact factor: 3.295